A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia

Romiplostim is a thrombopoietin (TPO) receptor agonist approved for children and adults with immune thrombocytopenia (ITP) for ≥6 months, recommended as second-line treatment. This phase 3b, single-arm, multicenter study investigated long-term efficacy and safety of romiplostim in children ≥1 to <...

Descripción completa

Detalles Bibliográficos
Autores principales: Grainger, John, Bussel, James, Tarantino, Michael, Cooper, Nichola, Beam, Donald, Despotovic, Jenny, Maschan, Alexey, Wang, Kejia, Eisen, Melissa, Bowers, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979726/
https://www.ncbi.nlm.nih.gov/pubmed/35413092
http://dx.doi.org/10.1182/bloodadvances.2021006014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979726/
https://www.ncbi.nlm.nih.gov/pubmed/35413092
http://dx.doi.org/10.1182/bloodadvances.2021006014

Ejemplares similares